ClinicalTrials.gg
CompletedNCT07020988Updated Feb 20, 2026

A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants

A Phase 1 interventional study of Staccato Alprazolam and Midazolam in Healthy Participants, sponsored by UCB Biopharma SRL. Completed at 1 site in United States. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to estimate the difference in the time to onset of action between Staccato alprazolam and intravenous (iv) midazolam using changes in power in the combined spindle and β1 frequency bands in the qEEG (quantitative electroencephalogram).

02

Conditions studied

  • Healthy Participants

Keywords

  • Phase 1
  • Staccato alprazolam
  • midazolam
  • diazepam
  • Healthy Study Participants
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 20 years to 55 years of age, inclusive, at the time of signing the ICF.
  • Participant is overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring, at the Screening Visit and on Day -1 of the single Intervention Period for the Pilot Part or on Day -1 of the first Intervention Period for the Main Part of the study.
  • Participant has a bodyweight of at least 45 kilograms (kg) (female) and 50 kg (male) and a within the range of 18 Kilograms per meter square (Kg/m2) to 30 kg/m2 (inclusive)
  • Participant has given which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in protocol.

Exclusion criteria

Exclusion Criteria:

  • Participant has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the participant's ability to participate in this study.
  • Participant has a history of chronic alcohol or drug abuse, as defined in the most recent version of the , within 6 months prior to the Screening Visit.
  • Participant has a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, neurological, cerebrovascular, or other major disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention; or interfering with the interpretation of data.
  • Participant has a history of or has been diagnosed with epilepsy or epileptic seizures.
  • Participant has abnormal EEG findings at Screening including background slowing (\<8Hz), focal slowing (focal δ-activity), or epileptiform discharges.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Pilot Part

    Study participants who successfully completed the Screening Period will receive single dose of Intravenous (IV) midazolam on Day 1 of the Intervention Period.

    Drug: Midazolam

  • Experimental
    Main Part-Group 1: Treatment Sequence AB

    Study participants randomized in Group 1 will receive Treatment A: Staccato Alprazolam on Day 1 of the Intervention Period 1 followed by Treatment B: IV Midazolam on Day 1 of the Intervention Period 2.

    Drug: Staccato Alprazolam · Drug: Midazolam

  • Experimental
    Main Part-Group 1: Treatment Sequence BA

    Study participants randomized in Group 1 will receive Treatment B: IV Midazolam on Day 1 of the Intervention Period 1 followed by Treatment A: Staccato Alprazolam on Day 1 of the Intervention Period 2.

    Drug: Staccato Alprazolam · Drug: Midazolam

  • Experimental
    Main Part-Group 2: Treatment Sequence AC

    Study participants randomized in Group 2 will receive Treatment A: Staccato Alprazolam on Day 1 of the Intervention Period 1 followed by Treatment C: Nasal Diazepam on Day 1 of the Intervention Period 2.

    Drug: Staccato Alprazolam · Drug: Diazepam

  • Experimental
    Main Part-Group 2: Treatment Sequence CA

    Study participants randomized in Group 2 will receive Treatment C: Nasal Diazepam on Day 1 of the Intervention Period 1 followed by Treatment A: Staccato Alprazolam on Day 1 of the Intervention Period 2.

    Drug: Staccato Alprazolam · Drug: Diazepam

Interventions

  • Study participants will receive single dose of Staccato Alprazolam at pre-specified time points.

    Also known as: UCB7538

  • Study participants will receive single dose of IV Midazolam at pre-specified time points.

  • Study participants will receive single dose of Nasal Diazepam by inhalation at pre-specified time points.

06

What researchers measure

Primary outcomes

  1. Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 minutes of study intervention administration of Staccato alprazolam in Group 1

    Time to reach a z-score of absolute power \>2 is derived from the z-scores over time for the combined spindle and β1 frequency bands. The z-scores are calculated using an algorithm applied to the quantitative electroencephalogram (qEEG) data recorded for each study participant.

    Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 1

  2. Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 minutes of study intervention administration of iv midazolam in Group 1

    Time to reach a z-score of absolute power \>2 is derived from the z-scores over time for the combined spindle and β1 frequency bands. The z-scores are calculated using an algorithm applied to the quantitative electroencephalogram (qEEG) data recorded for each study participant.

    Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 1

Secondary outcomes

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs) from the first study intervention administration to the Safety Follow-Up (SFU) Visit/ Early Termination Visit (ETV)

    Treatment Emergent Adverse Events (TEAEs) are any untoward medical incidence in a participant after the administration of study treatment, whether or not these events are related to study treatment.

    Time frame: From the first study intervention administration to the Safety Follow-Up (SFU) Visit/ Early Termination Visit (ETV) (up to 55 Days)

  2. Occurrence of Serious TEAEs from the first study intervention administration to the Safety Follow-Up (SFU) Visit/ Early Termination Visit (ETV)

    Serious Treatment-Emergent Adverse Events (Serious TEAEs) are any untoward medical incidence in a participant during administered study treatment, whether or not these events are related to study treatment and additionally are emergent untoward medical occurrence that at any dose: Results in death; Is life-threatening; Requires in patient hospitalisation or prolongation of existing hospitalisation; Results in persistent disability/incapacity; Is a congenital anomaly or birth defect; Important medical events.

    Time frame: From the first study intervention administration to the Safety Follow-Up (SFU) Visit/ Early Termination Visit (ETV) (up to 55 Days)

  3. Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 Minutes of study intervention administration of Staccato alprazolam in Group 2

    Time to reach a z-score of absolute power \>2 is derived from the z-scores over time for the combined spindle and β1 frequency bands. The z-scores are calculated using an algorithm applied to the qEEG data recorded for each study participant.

    Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 2

  4. Time to reach a z-score of absolute power >2 and maintained for at least 60 seconds in the combined spindle and β1 frequency bands within the first 60 Minutes of study intervention administration of nasal diazepam in Group 2

    Time to reach a z-score of absolute power \>2 is derived from the z-scores over time for the combined spindle and β1 frequency bands. The z-scores are calculated using an algorithm applied to the qEEG data recorded for each study participant.

    Time frame: Within the first 60 minutes of the study intervention administration on Day 1 of the Intervention Period in Group 2

  5. Maximum concentration (Cmax) of alprazolam

    Cmax=maximum concentration

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

  6. Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC[0-t]) of alprazolam

    AUC(0-t)=area under the concentration-time curve from time 0 to the last quantifiable concentration

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

  7. Area Under the Concentration Time Curve From Time 0 to Infinity (AUC) of alprazolam

    AUC=area under the concentration-time curve from time 0 to infinity

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

  8. Maximum concentration (Cmax) of midazolam

    Cmax=maximum concentration

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

  9. Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC[0-t]) of midazolam

    AUC(0-t)=area under the concentration-time curve from time 0 to the last quantifiable concentration

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

  10. Area Under the Concentration Time Curve From Time 0 to Infinity (AUC) of midazolam

    AUC=area under the concentration-time curve from time 0 to infinity

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

  11. Maximum concentration (Cmax) of diazepam

    Cmax=maximum concentration

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

  12. Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC[0-t]) of diazepam

    AUC(0-t)=area under the concentration-time curve from time 0 to the last quantifiable concentration

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

  13. Area Under the Concentration Time Curve From Time 0 to Infinity (AUC) of diazepam

    AUC=area under the concentration-time curve from time 0 to infinity

    Time frame: Plasma samples will be collected at predose (Day 1) and at pre-defined time points upto 24 hours postdose

07

Study locations

1 site
  • Up0127 1001
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No — Due to the small sample size in this trial, individual patient-level data (IPD) cannot be adequately anonymized as, there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Jan 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2025
First posted
Jun 13, 2025
StartActual
Jun 12, 2025
Primary completionActual
Jan 6, 2026
CompletionActual
Jan 21, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07020988
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Jun 12, 2025
Primary completion
Jan 6, 2026
Completion
Jan 21, 2026
Last update
Feb 20, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alprazolam · Midazolam · Diazepam

Start the discussion